Item 5.02. Departure of Directors or Certain Officers; Election of Directors;


           Appointment of Certain Officers; Compensatory Arrangements of Certain
           Officers.

(b) On January 6, 2023, Annexon, Inc. (the "Company") announced the appointment of Dean Richard Artis, Ph.D. as Chief Scientific Officer of the Company. Dr. Artis is succeeding Larry C. Mattheakis, Ph.D., who is departing from the Company and is no longer serving as Chief Scientific Officer effective as of January 6, 2023.

Item 7.01. Regulation FD Disclosure.

A copy of the press release, dated January 6, 2023, announcing the appointment of Dr. Artis to his position, is furnished as Exhibit 99.1 hereto and is incorporated by reference herein.

The information in this Item 7.01 of this Current Report on Form 8-K and Exhibit 99.1 attached hereto shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information contained herein and in the accompanying exhibit shall not be incorporated by reference into any filing with the Securities and Exchange Commission made by the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing.

Item 9.01. Financial Statements and Exhibits.




(d) Exhibits.

Exhibit
  No.                                    Description

 99.1        Press Release, dated January 6, 2023, titled "Annexon Appoints
           Industry Veteran, Dr. Rick Artis, as Chief Scientific Officer to
           Support the Advancement and Expansion of Complement-focused Portfolio."


104.1      Cover Page Interactive Data File, formatted in inline XBRL.

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses